Summary

Treatment with AVP-825 significantly reduces headache-associated burden and functional disability. Improvements are seen as early as 45 minutes after treatment, with significant percentages of patients reporting either mild or no disability by 120 minutes postdose. Headache response, improvement in functioning, and reduction in disability corresponded with the rates of patient-reported meaningful relief.